Cryo-Cell International, Inc. (CCEL)
| Market Cap | 54.85M |
| Revenue (ttm) | 31.99M |
| Net Income (ttm) | 402,095 |
| Shares Out | 8.06M |
| EPS (ttm) | 0.05 |
| PE Ratio | 135.88 |
| Forward PE | 56.00 |
| Dividend | $0.25 (3.72%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 32,037 |
| Open | 7.90 |
| Previous Close | 7.90 |
| Day's Range | 6.52 - 7.90 |
| 52-Week Range | 4.99 - 9.50 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 14, 2025 |
About CCEL
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer’s disease, Parkinson’s diseases. The company manufacture... [Read more]
Financial Performance
Financial StatementsNews
Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announ...
Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announ...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, anno...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced r...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced ...
Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company” or “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 19...
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced r...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, anno...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced r...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced ...
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022
OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in ...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2022 Financial Results
OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem ce...
Cord Blood Banking Leader Cryo-Cell Announces Special Cash Dividend
OLDSMAR, Fla., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store ste...
Cord Blood Banking Leader Cryo-Cell Announces Transfer to the NYSE American Stock Exchange
OLDSMAR, Fla., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (“Cryo-Cell”, the “Company”), the world's first private cord blood bank to separat...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2022 Financial Results
OLDSMAR, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store s...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2022 Financial Results
OLDSMAR, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store ste...
Cord Blood Banking Leader Cryo-Cell Announces Extravault Biorepository Service
OLDSMAR, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store ...
Cryo-Cell Shares Its 2021 Annual Letter to Shareholders
OLDSMAR, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store ...
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2021
OLDSMAR, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store s...
Cryo-Cell International: A Stable Business Paired With An Upcoming Catalyst
Cryo-Cell International has a stable business that generates consistent cash flow. The company is close to monetizing a partnership with Duke University to bring patented stem cell treatments to marke...
Cord Blood Banking Leader Cryo-Cell Announces Its Intent to Advance Clinical Trials
OLDSMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store s...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2021 Financial Results
OLDSMAR, Fla., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store s...
Cryo-Cell International Announces Changes To Its Board of Directors
MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (Nasdaq:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy...
Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market
Cryo-Cell International, Inc. (Symbol CCEL), The Leader In Cord Blood And Cord Tissue Cryopreservation Services, Today Announced That The Company's Common Stock Has Been Approved For Listing On The Na...
Cryo-Cell International Completes Acquisition of Real Estate Property for Its Institute for Cellular Therapies
Cryo-Cell International (symbol: CCEL) Purchases Real Estate Location for its Institute for Cellular Therapies in the Raleigh-Durham area.